PAREXEL Launches IMPACT® Express Clinical Trial Management System
December 01 2015 - 9:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today introduced
IMPACT® Express Clinical Trial Management System (CTMS). IMPACT
Express provides a quick-to-implement, cost-effective clinical
trial management solution to simplify clinical trial management and
monitoring for small to mid-sized biopharmaceutical companies.
Clinical trials are the most expensive component of the drug
development process. Use of a single, unified clinical trial
management system plays a vital role in helping biopharmaceutical
companies’ plan, track, record, and oversee the complex array of
administrative, financial, site-related, and other activities that
are critical for the efficient monitoring and management of
clinical trials.
“PAREXEL developed IMPACT Express for biopharmaceutical and
biotech companies in need of a scalable, rapid-to-deploy and
cost-effective CTMS option to intelligently manage the complexities
of clinical trials,” said Patrick Nadolny, Vice President of
Product Management, Data and Analytics Services, PAREXEL
Informatics. “By applying a process-driven approach to trial
management and monitoring, biopharma companies will be better able
to save time – and money – while simplifying their drug development
journey.”
IMPACT Express draws on PAREXEL Informatics’ commitment to
operational excellence and 20+ years of investment in CTMS
innovations and process improvements coupled with the feedback and
hands-on experiences of users around the world. Biopharmaceutical,
medical device and research organizations of all sizes have used
PAREXEL’s CTMS solutions to manage more than 25,000 trials.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 80
locations in 51 countries around the world, and had approximately
18,620 employees in the first quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, and IMPACT are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151201005278/en/
PAREXEL InternationalCristi Barnett,
+1-781-434-4019Cristi.Barnett@PAREXEL.comorPAN
CommunicationsMatthew Briggs,
+1-617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024